Virginiamycin S1

Summary

Virginiamycin S1 is a streptogramin B peptide antibiotic approved for use in animal production and ethanol‑fuel fermentations. It is added to discourage growth of undesirable bacteria during ethanol production and may be employed as a feed additive for livestock. The compound is administered orally or by subcutaneous injection.

Mechanism of Action

Binds to the 50S ribosomal subunit at the peptidyl transferase center, blocking the exit tunnel and inhibiting elongation and translocation of peptide chains; acts synergistically with streptogramin A components (e.g., virginiamycin M1) to produce irreversible, bactericidal inhibition

What the Research Shows

Recent studies have focused on detecting virginiamycin S1 residues in agricultural and industrial streams. Advanced solid‑phase extraction and LC‑MS/MS methods have quantified the antibiotic in vinasse from sugarcane ethanol plants and in distillers grains used as animal feed, revealing low‑nanogram per milliliter levels. Genomic analysis of the rare actinobacterium Kutzneria chonburiensis identified a biosynthetic gene cluster predicted to produce virginiamycin S1, expanding knowledge of its natural source. A 1986 labeling experiment clarified that phenylglycine formation in its biosynthesis proceeds via an intermolecular nitrogen‑transfer pathway.

Reported Benefits

The primary benefit reported is its ability to suppress contaminating bacteria in ethanol fermentations, helping maintain ethanol yield and quality. When used as a livestock feed additive, it contributes to growth promotion and disease prevention, consistent with its classification as a streptogramin antibiotic.

Limitations of the Evidence

Evidence for therapeutic efficacy in humans or veterinary disease treatment is not presented. Environmental monitoring studies highlight that residues can persist in vinasse and distillers grains, raising concerns about ecological impact and antimicrobial‑resistance development. No clinical trial data are available, and the literature is limited to analytical and genomic investigations.

Safety Considerations

Residues of virginiamycin S1 have been detected in by‑products used for animal feed, suggesting potential exposure to non‑target species. While no specific adverse‑event data are reported, the presence of low‑level residues may contribute to antimicrobial‑resistance pressures. Regulatory surveillance relies on sensitive analytical methods to ensure residue levels remain within safety thresholds.

How It Is Administered

Virginiamycin S1 can be delivered orally or by subcutaneous injection. Commercial formulations are typically supplied as powders or solutions suitable for incorporation into feed or for injection, but specific product details are not provided in the cited literature.

Routes of Administration

Goals & Uses

• Gram-positive bacterial infection treatmentAntimicrobialModerate
• MRSA and resistant Gram-positive infectionsAntimicrobial ResistanceLow
• Livestock growth promotionVeterinary/agriculturalHigh
• Ribosomal biology research toolResearchHigh
• Antibacterial activityInfectious DiseaseHigh

Contraindications

• Concurrent use with drugs metabolized by CYP3A4Drug InteractionModerate
• Human useClinicalHigh
• Hypersensitivity to streptogramin antibioticsAllergyHigh

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• Arthralgia/myalgiaMusculoskeletalUncommon
• Injection site reactionsLocalCommon
• Gastrointestinal disturbanceGastrointestinalCommon
• Antibiotic resistance developmentMicrobialUnknown

Drug Interactions

• Other protein synthesis inhibitorsModerate
• CYP3A4 substrates (e.g., cyclosporine, tacrolimus, statins)High
• WarfarinModerate
• Chloramphenicol / lincosamidesModerate

Population Constraints

• PregnancyReproductive SafetyRelative
• Hepatic impairmentOrgan FunctionRelative
• Poultry and swineSpeciesRelative
• Human patientsClinicalAbsolute
• Pediatric populationAgeRelative

Regulatory Status

• European UnionWithdrawnBanned as growth promoter; restricted veterinary use.
• United StatesUnapprovedNot approved for human use; limited veterinary use under specific conditions.
• United KingdomWithdrawnSimilar to EU restrictions.

Virginiamycin as a combination product (M1 + S1) has been used as a veterinary/agricultural growth promotant in several countries but has faced bans or restrictions in the EU due to concerns over cross-resistance with quinupristin/dalfopristin. The isolated S1 component alone is not an approved pharmaceutical agent in any major jurisdiction.

Evidence & Sources

• Sample preparation and antibiotic quantification in vinasse generated from sugarcane ethanol fuel production
  Journal ArticleLowda Silva JJ, et al.2022-01-01T00:00:00.000000Z
• Comparative genome features and secondary metabolite biosynthetic potential of Kutzneria chonburiensis and other species of the genus Kutzneria
  Journal ArticleLowChanama M, Prombutara P, Chanama S2023-01-01T00:00:00.000000Z
• LC-MS/MS Determination of Antibiotic Residues in Distillers Grains: Method Modification
  Journal ArticleLowDe Alwis HG, Nochetto C2023-01-01T00:00:00.000000Z
• Biosynthesis of antibiotics of the virginiamycin family, 5. The conversion of phenylalanine to phenylglycine in the biosynthesis of virginiamycin S1
  Journal ArticleLowReed JW, Kingston DG1986-01-01T00:00:00.000000Z
• An LC-MS/MS method for the determination of antibiotic residues in distillers grains
  Journal ArticleLowDuelge KJ, Nishshanka U, De Alwis HG2017-01-01T00:00:00.000000Z

Frequently Asked Questions